

Maarten P Van Den Berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3110376/publications.pdf>

Version: 2024-02-01

82
papers

4,167
citations

136950

32
h-index

123424

61
g-index

86
all docs

86
docs citations

86
times ranked

6084
citing authors

#	ARTICLE	IF	CITATIONS
1	Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1492-1501.	1.2	6
2	Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , 2022, 24, 296-305.	1.7	9
3	Pathophysiological pathways in patients with heart failure and atrial fibrillation. <i>Cardiovascular Research</i> , 2022, 118, 2478-2487.	3.8	5
4	Sex-specific aspects of phospholamban cardiomyopathy: The importance and prognostic value of low-voltage electrocardiograms. <i>Heart Rhythm</i> , 2022, 19, 427-434.	0.7	8
5	An International Multicenter Cohort Study on β -Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation</i> , 2022, 145, 333-344.	1.6	28
6	Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility. <i>Nature Genetics</i> , 2022, 54, 232-239.	21.4	55
7	Clinical Characteristics and Follow-Up of Pediatric-Onset Arrhythmogenic Right Ventricular Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2022, 8, 306-318.	3.2	10
8	Functional investigation of two simultaneous or separately segregating <i>DSP</i> variants within a single family supports the theory of a dose-dependent disease severity. <i>Experimental Dermatology</i> , 2022, , .	2.9	3
9	A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. <i>European Heart Journal</i> , 2022, 43, e1-e9.	2.2	35
10	Value of genetic testing in the diagnosis and risk stratification of arrhythmogenic right ventricular cardiomyopathy. <i>Heart Rhythm</i> , 2022, 19, 1659-1665.	0.7	6
11	Early Mechanical Alterations in Phospholamban Mutation Carriers. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 885-896.	5.3	11
12	Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e008509.	4.8	82
13	Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls. <i>Genetics in Medicine</i> , 2021, 23, 47-58.	2.4	57
14	The effect of tropomyosin variants on cardiomyocyte function and structure that underlie different clinical cardiomyopathy phenotypes. <i>International Journal of Cardiology</i> , 2021, 323, 251-258.	1.7	8
15	The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2955.	4.1	9
16	Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers "reaching the frontiers of individual risk prediction. <i>European Heart Journal</i> , 2021, 42, 2842-2850.	2.2	54
17	TAB2 deletions and variants cause a highly recognisable syndrome with mitral valve disease, cardiomyopathy, short stature and hypermobility. <i>European Journal of Human Genetics</i> , 2021, 29, 1669-1676.	2.8	19
18	Gain-of-function mutation in ubiquitin ligase KLHL24 causes desmin degradation and dilatation in hiPSC-derived engineered heart tissues. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	22

#	ARTICLE	IF	CITATIONS
19	Aortic distensibility in Marfan syndrome: a potential predictor of aortic events?. <i>Open Heart</i> , 2021, 8, e001775.	2.3	7
20	Genome-wide methylation patterns in Marfan syndrome. <i>Clinical Epigenetics</i> , 2021, 13, 217.	4.1	7
21	Coexistence of wild type and hereditary ATTR amyloidosis in one family. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 71-72.	3.0	0
22	Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome. <i>Circulation</i> , 2020, 142, 324-338.	1.6	83
23	Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial. <i>European Heart Journal</i> , 2020, 41, 4181-4187.	2.2	54
24	The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy. <i>Scientific Reports</i> , 2020, 10, 9819.	3.3	38
25	Heart Rate Recovery After Exercise Is Associated With Arrhythmic Events in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e007471.	4.8	10
26	Homozygous damaging SOD2 variant causes lethal neonatal dilated cardiomyopathy. <i>Journal of Medical Genetics</i> , 2020, 57, 23-30.	3.2	16
27	Cardiac Transthyretin-derived Amyloidosis: An Emerging Target in Heart Failure with Preserved Ejection Fraction?. <i>Cardiac Failure Review</i> , 2020, 6, e21.	3.0	2
28	Heritability in genetic heart disease: the role of genetic background. <i>Open Heart</i> , 2019, 6, e000929.	2.3	17
29	Dyssynchronopathy Can be a Manifestation of Heritable Cardiomyopathy. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002528.	3.6	0
30	Three female patients with Danon disease presenting with predominant cardiac phenotype: a case series. <i>European Heart Journal - Case Reports</i> , 2019, 3, ytz132.	0.6	6
31	Incidence and predictors of implantable cardioverter-defibrillator therapy and its complications in idiopathic ventricular fibrillation patients. <i>Europace</i> , 2019, 21, 1519-1526.	1.7	20
32	Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. <i>European Heart Journal</i> , 2019, 40, 2953-2961.	2.2	96
33	Mortality Risk Associated With Truncating Founder Mutations in Titin. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002436.	3.6	5
34	Relevance of Titin Missense and Non-Frameshifting Insertions/Deletions Variants in Dilated Cardiomyopathy. <i>Scientific Reports</i> , 2019, 9, 4093.	3.3	30
35	Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. <i>European Heart Journal</i> , 2019, 40, 1287-1293.	2.2	39
36	Distinct molecular signature of phospholamban p.Arg14del arrhythmogenic cardiomyopathy. <i>Cardiovascular Pathology</i> , 2019, 40, 2-6.	1.6	16

#	ARTICLE	IF	CITATIONS
37	The Prognostic Value of Right Ventricular Deformation Imaging in Early Arrhythmogenic Right Ventricular Cardiomyopathy. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 446-455.	5.3	64
38	Myocardial fibrosis as an early feature in phospholamban p.Arg14del mutation carriers: phenotypic insights from cardiovascular magnetic resonance imaging. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 92-100.	1.2	48
39	Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. <i>Journal of Clinical Investigation</i> , 2019, 129, 3171-3184.	8.2	42
40	Toward an effective exome-based genetic testing strategy in pediatric dilated cardiomyopathy. <i>Genetics in Medicine</i> , 2018, 20, 1374-1386.	2.4	36
41	Genetics, Clinical Features, and Long-Term Outcome of Noncompaction Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2018, 71, 711-722.	2.8	242
42	Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension Syndrome. <i>Circulation Research</i> , 2018, 122, 846-854.	4.5	22
43	A common co-morbidity modulates disease expression and treatment efficacy in inherited cardiac sodium channelopathy. <i>European Heart Journal</i> , 2018, 39, 2898-2907.	2.2	17
44	SCN5A mutation type and topology are associated with the risk of ventricular arrhythmia by sodium channel blockers. <i>International Journal of Cardiology</i> , 2018, 266, 128-132.	1.7	21
45	Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1004-1009.	1.7	15
46	The electrocardiographic manifestations of athlete's heart and their association with exercise exposure. <i>European Journal of Sport Science</i> , 2018, 18, 587-593.	2.7	9
47	The first titin (c.59926 + 1G > A) founder mutation associated with dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2018, 20, 803-806.	7.1	16
48	Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. <i>American Journal of Cardiology</i> , 2018, 121, 107-112.	1.6	22
49	Effect of Ascertainment Bias on Estimates of Patient Mortality in Inherited Cardiac Diseases. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e001797.	3.6	10
50	Electrocardiographic Features Differentiating Arrhythmogenic Right Ventricular Cardiomyopathy From an Athlete's Heart. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1613-1625.	3.2	19
51	No major role for rare plectin variants in arrhythmogenic right ventricular cardiomyopathy. <i>PLoS ONE</i> , 2018, 13, e0203078.	2.5	2
52	Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. <i>Cardiovascular Research</i> , 2017, 113, 102-111.	3.8	148
53	Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). <i>Cardiovascular Pathology</i> , 2017, 29, 19-22.	1.6	3
54	Follow-up care by a genetic counsellor for relatives at risk for cardiomyopathies is cost-saving and well-appreciated: a randomised comparison. <i>European Journal of Human Genetics</i> , 2017, 25, 169-175.	2.8	8

#	ARTICLE	IF	CITATIONS
55	Phospholamban immunostaining is a highly sensitive and specific method for diagnosing phospholamban p.Arg14del cardiomyopathy. <i>Cardiovascular Pathology</i> , 2017, 30, 23-26.	1.6	17
56	Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. <i>European Journal of Heart Failure</i> , 2017, 19, 512-521.	7.1	127
57	Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. <i>Heart</i> , 2016, 102, 303-312.	2.9	50
58	Phospholamban p.Arg14del cardiomyopathy is characterized by phospholamban aggregates, aggresomes, and autophagic degradation. <i>Histopathology</i> , 2016, 69, 542-550.	2.9	46
59	Sudden Cardiac Arrest and Rare Genetic Variants in the Community. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 147-153.	5.1	27
60	Genotype impacts survival in Marfan syndrome. <i>European Heart Journal</i> , 2016, 37, 3285-3290.	2.2	114
61	Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 463-469.	2.9	35
62	Hypertrophic remodelling in cardiac regulatory myosin light chain (<i>MYL2</i>) founder mutation carriers. <i>European Heart Journal</i> , 2016, 37, 1815-1822.	2.2	63
63	Transthyretin-Derived (ATTR) Amyloidotic Cardiomyopathy After Receiving a Domino Liver Allograft. <i>Circulation</i> , 2015, 132, e216-7.	1.6	8
64	Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. <i>European Heart Journal</i> , 2015, 36, 847-855.	2.2	338
65	Bone scintigraphy with ^{99m} technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 35-44.	3.0	129
66	Clinical utility gene card for: arrhythmogenic right ventricular cardiomyopathy (ARVC). <i>European Journal of Human Genetics</i> , 2014, 22, 293-293.	2.8	27
67	A new fully covered metal stent with anti-migration features for the treatment of malignant dysphagia. <i>Endoscopy</i> , 2014, 46, 1101-1105.	1.8	22
68	Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy. <i>Open Heart</i> , 2014, 1, e000116.	2.3	40
69	Symptom severity is associated with cardiovascular outcome in patients with permanent atrial fibrillation in the RACE II study. <i>Europace</i> , 2014, 16, 1417-1425.	1.7	29
70	Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2165-2173.	2.2	159
71	Periprocedural Complications and Long-Term Outcome After Alcohol Septal Ablation Versus Surgical Myectomy in Hypertrophic Obstructive Cardiomyopathy. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1227-1234.	2.9	64
72	Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort. <i>Circulation: Heart Failure</i> , 2014, 7, 723-731.	3.9	74

#	ARTICLE	IF	CITATIONS
73	Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization. <i>Nature Genetics</i> , 2014, 46, 826-836.	21.4	281
74	Successful treatment of a patient with symptomatic long QT syndrome type 3 using ranolazine combined with a beta-blocker. <i>International Journal of Cardiology</i> , 2014, 171, 90-92.	1.7	20
75	Outcome in Phospholamban R14del Carriers. <i>Circulation: Cardiovascular Genetics</i> , 2014, 7, 455-465.	5.1	146
76	Digoxin in patients with permanent atrial fibrillation: Data from the RACE II study. <i>Heart Rhythm</i> , 2014, 11, 1543-1550.	0.7	62
77	Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. <i>European Journal of Heart Failure</i> , 2012, 14, 1199-1207.	7.1	369
78	Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?. <i>European Journal of Heart Failure</i> , 2010, 12, 1297-1299.	7.1	27
79	Rhythmic ECG Changes in a Patient with Long QT Syndrome Type 3. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 1342-1343.	1.7	2
80	Diurnal variation of ventricular repolarization in a large family with LQT3-Brugada syndrome characterized by nocturnal sudden death. <i>Heart Rhythm</i> , 2006, 3, 290-295.	0.7	22
81	Brugada Syndrome with ST-Segment Elevation in the Lateral Leads. <i>Journal of Cardiovascular Electrophysiology</i> , 2006, 17, 1035-1035.	1.7	13
82	Brugada electrocardiographic pattern elicited by cyclic antidepressants overdose. <i>Intensive Care Medicine</i> , 2006, 32, 281-285.	8.2	24